Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial
Iain B. McInnes, Frank Behrens, Philip J. Mease, Arthur Kavanaugh, Christopher T. Ritchlin, Peter Nash, Jordi Gratacós, Philippe Goupille, Т. В. Коротаева, Alice B. Gottlieb, Ruvie Martin, Kevin Ding, Pascale Pellet, Shephard Mpofu, Luminita Pricop
Topics & Concepts
MedicineSecukinumabAdalimumabPsoriatic arthritisDermatologyDouble blindArthritisPsoriasisInternal medicinePlaceboRheumatoid arthritisAlternative medicinePathologySpondyloarthritis Studies and TreatmentsRheumatoid Arthritis Research and TherapiesPsoriasis: Treatment and Pathogenesis